Company / EPS (Diluted)
TG Therapeutics, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.09
FY2025
5-year range
-$2.63 / $0.09
FY2021-FY2025
Trend
+105.5%
vs FY2024
Sector context
#45 of 204
Health Care
What the data says
TG Therapeutics, Inc.'s eps (diluted) of $0.09 is higher than 78% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 8 years, ranging from $-2.63 in FY2023 to $0.09 in FY2025.
Based on SEC 10-K filings.
0.09 in FY2025. Top quartile in the Health Care sector.
Improved from $-2.63 to $0.09 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 204This company $0.09 Sector average -$0.89
▼
+110.2% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 105.5% year-over-year.
- Ranks #45 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.09 | +105.5% |
| FY2024 | -$1.65 | +37.3% |
| FY2023 | -$2.63 | -8.7% |
| FY2022 | -$2.42 | -23.5% |
| FY2021 | -$1.96 | +14.8% |
| FY2020 | -$2.30 | -20.4% |
| FY2019 | -$1.91 | -19.4% |
| FY2018 | -$1.60 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026